Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

D. Wolchok, Jedd; Chiarion‐Sileni, Vanna; González, René; Rutkowski, Piotr; Grob, Jean‐Jacques; Lance Cowey, C.; D. Lao, Christopher; Wagstaff, John; Schadendorf, Dirk; Francesco Ferrucci, Pier; Smylie, Michael; Dummer, Reinhard; Hill, Andrew; Hogg, David; B.A.G. Haanen, John; S. Carlino, Matteo; Bechter, Oliver; Maio, Michele; Márquez‐Rodas, Iván; Guidoboni, Massimo; A. McArthur, Grant; Lebbé, Célèste; A. Ascierto, Paolo; V. Long, Georgina; Cebon, Jonathan; A. Sosman, Jeffrey; A. Postow, Michael; K. Callahan, Margaret; Walker, Dana; Rollin, Linda; Bhore, Rafia; Stephen Hodi, F.; Larkin, James

doi:10.1056/nejmoa1709684

Public

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Published in New England Journal of Medicine • Sep 11, 2017

Authors:

Jedd D. Wolchok

Vanna Chiarion‐Sileni

René González

Abstract

BACKGROUND: Nivolumab combined with ipilimumab resulted in longer progression-free survival and a higher objective response rate than ipilimumab alone in a phase 3 trial involving patients with advanced melanoma. We now report 3-year overall survival outcomes in this trial. METHODS: We randomly assi...

Subject

Ipilimumab

Nivolumab

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!